Dr. Reddy's Laboratories ...

AI Score

0

Unlock

15.28
-0.03 (-0.20%)
At close: Jan 14, 2025, 3:59 PM
undefined%
Bid 15.13
Market Cap 12.73B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.77
PE Ratio (ttm) 19.84
Forward PE n/a
Analyst Buy
Ask 15.29
Volume 844,220
Avg. Volume (20D) 1,290,755
Open 15.31
Previous Close 15.31
Day's Range 15.15 - 15.35
52-Week Range 13.43 - 16.89
Beta undefined

About RDY

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finish...

Sector Healthcare
IPO Date Apr 11, 2001
Employees 27,048
Stock Exchange NYSE
Ticker Symbol RDY

Analyst Forecast

According to 1 analyst ratings, the average rating for RDY stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 11.26% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Dr. Reddy's Laboratories Limited is scheduled to release its earnings on Jan 23, 2025, before market opens.
Analysts project revenue of $964.48M, reflecting a 11.24% YoY growth and earnings per share of 0.19, making a -5.00% decrease YoY.
6 months ago · Source
+4.65%
Dr. Reddy's Laboratories shares are trading higher... Unlock content with Pro Subscription
8 months ago · Source
-4.74%
Dr Reddy's Laboratories shares are trading lower following a Q4 revenue miss.